Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Avadel Pharmaceuticals Plc (AVDL)

Avadel Pharmaceuticals Plc (AVDL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 339,297
  • Shares Outstanding, K 37,450
  • Annual Sales, $ 59,220 K
  • Annual Income, $ -33,230 K
  • 60-Month Beta 1.18
  • Price/Sales 5.94
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -0.28
  • Number of Estimates 2
  • High Estimate -0.24
  • Low Estimate -0.31
  • Prior Year -0.35
  • Growth Rate Est. (year over year) +20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.00 +118.00%
on 03/18/20
10.75 -18.88%
on 03/03/20
-1.27 (-12.71%)
since 02/28/20
3-Month
4.00 +118.00%
on 03/18/20
10.75 -18.88%
on 03/03/20
+1.44 (+19.78%)
since 12/27/19
52-Week
1.03 +746.60%
on 04/29/19
10.75 -18.88%
on 03/03/20
+7.28 (+505.56%)
since 03/29/19

Most Recent Stories

More News
Jazz's (JAZZ) Xyrem Follow-On Candidate NDA Gets FDA Acceptance

The FDA accepts Jazz's (JAZZ) regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem in the United States.

TEVA : 8.51 (+12.57%)
NVS : 81.90 (+3.30%)
JAZZ : 99.60 (+2.72%)
AVDL : 8.72 (-3.75%)
Avadel Pharmaceuticals Completes the REST-ON Phase 3 Pivotal Trial of FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy...

AVDL : 8.72 (-3.75%)
Avadel: 4Q Earnings Snapshot

DUBLIN (AP) _ Avadel Pharmaceuticals PLC (AVDL) on Thursday reported a loss of $2.7 million in its fourth quarter.

AVDL : 8.72 (-3.75%)
Avadel Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

EQNX::TICKER_START (NASDAQ:AVDL), EQNX::TICKER_END

AVDL : 8.72 (-3.75%)
Avadel Pharmaceuticals Plc to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 12, 2020 / Avadel Pharmaceuticals Plc (NASDAQ:AVDL) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 12, 2020 at...

AVDL : 8.72 (-3.75%)
Avadel Pharmaceuticals to Report Fourth Quarter and Year End 2019 Financial Results on March 12th

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy...

AVDL : 8.72 (-3.75%)
Avadel Pharmaceuticals Announces $65 Million Private Placement with Leading Biotech Investment Funds

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy...

AVDL : 8.72 (-3.75%)
Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258 (Revised)

Jazz (JAZZ) files regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem, in the United States.

NVS : 81.90 (+3.30%)
AVDL : 8.72 (-3.75%)
JAZZ : 99.60 (+2.72%)
TEVA : 8.51 (+12.57%)
Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258

Jazz (JAZZ) files regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem, in the United States.

NVS : 81.90 (+3.30%)
AVDL : 8.72 (-3.75%)
JAZZ : 99.60 (+2.72%)
TEVA : 8.51 (+12.57%)
Jazz's (JAZZ) New Sleep Drug Sunosi Gets Approval in Europe

Jazz (JAZZ) receives approval for Sunosi as a treatment for excessive daytime sleepiness in narcolepsy or obstructive sleep apnea patients in Europe.

NVS : 81.90 (+3.30%)
AVDL : 8.72 (-3.75%)
JAZZ : 99.60 (+2.72%)
TEVA : 8.51 (+12.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade AVDL with:

Business Summary

Avadel Pharmaceuticals plc is a specialty pharmaceutical company. Its product pipeline consists of hospital and paediatrics. Hospital segment provides Bloxiverz(R), Vazculep(R) and Akovaz(TM). Paediatrics segment provides Karbinal (TM) ER, AcipHex(R) Sprinkle and Flexichamber(TM). The company operates...

See More

Key Turning Points

2nd Resistance Point 9.71
1st Resistance Point 9.21
Last Price 8.72
1st Support Level 8.31
2nd Support Level 7.91

See More

52-Week High 10.75
Last Price 8.72
Fibonacci 61.8% 7.04
Fibonacci 50% 5.89
Fibonacci 38.2% 4.74
52-Week Low 1.03

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar